UK Approves Stronger Wegovy Dose Amid Soaring Demand

The UK's medicines regulator, the MHRA, has approved a significantly stronger 7.2mg dose of the weight loss drug Wegovy. This new dosage, three times the previous maximum of 2.4mg per week, has demonstrated the potential to achieve over 20% weight loss in clinical trials, with a third of participants losing more than 25% of their body weight.

This advancement coincides with a surge in demand for weight loss medications. Recent surveys indicate millions have used drugs like Wegovy and Mounjaro, with many more expressing interest in future use. Researchers caution against using these diabetes medications off-label for weight loss due to potential safety risks without proper clinical oversight.

Further research indicates that while these jabs promote weight loss during treatment, patients tend to regain the lost weight within approximately 20 months of stopping. This contrasts with sustained weight management achieved through diet and exercise, which lasts nearly four years on average. The improvements in health markers associated with the jabs are also lost upon cessation.